WASHINGTON, DC – As insulin prices continue to climb and Americans throughout the nation risk their lives by rationing their insulin supplies, U.S. Senator Jeanne Shaheen (D-NH) announced new legislation to combat these skyrocketing costs and hold health care middlemen accountable. Shaheen’s bipartisan bill – the Insulin Price Reduction Act – would hold pharmacy benefit managers (PBMs), big pharmaceutical companies and insurers accountable for these surging prices by incentivizing reductions in list prices. Shaheen introduced the legislation today with Senators Kevin Cramer (R-ND), Susan Collins (R-ME), and Tom Carper (D-DE).

“Insulin is a life-saving drug for those with diabetes, but the price continues escalating to unaffordable lengths,” said Senator Cramer. “Our legislation incentivizes lower list prices by tackling rebates and deductibles, which could significantly change the insulin pricing model and finally ease the sticker shock North Dakotans and Americans experience every month.”

The full release can be found here